We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Norepinephrine for Spinal-induced Hypotension (NE in spianl)

This study is not yet open for participant recruitment.
Verified October 2017 by AlRefaey Kandeel, Mansoura University
Sponsor:
ClinicalTrials.gov Identifier:
NCT03308708
First Posted: October 12, 2017
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
AlRefaey Kandeel, Mansoura University
  Purpose
Norepinephrine (NE) infusion is used prophylactically to counteract the vasodilator effect of spinal anesthesia. prophylactic use of NE infusion is expected to decrease bouts of hypotension, vomiting and increase patient satisfaction

Condition Intervention
Spinal Anesthesia Drug: Norepinephrine infusion

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Prophylactic Norepinephrine Infusion for Spinal-induced Hypotension

Resource links provided by NLM:


Further study details as provided by AlRefaey Kandeel, Mansoura University:

Primary Outcome Measures:
  • incidence of hypotension [ Time Frame: intraoperative ]
    intraoperative decrease of patient blood pressure by more than 20% from its basal reading


Estimated Enrollment: 50
Anticipated Study Start Date: November 1, 2017
Estimated Study Completion Date: January 1, 2018
Estimated Primary Completion Date: January 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control group
Experimental: NE group Drug: Norepinephrine infusion
Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All patients scheduled for elective surgery under spinal anesthesia

Exclusion Criteria:

  • ischemic heart disease uncontrolled hypertension
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03308708


Locations
Egypt
Mansoura university
Al Manşūrah, Dkahleya, Egypt
Sponsors and Collaborators
Mansoura University
  More Information

Responsible Party: AlRefaey Kandeel, Dr, Mansoura University
ClinicalTrials.gov Identifier: NCT03308708     History of Changes
Other Study ID Numbers: NE_spinal
First Submitted: October 9, 2017
First Posted: October 12, 2017
Last Update Posted: October 12, 2017
Last Verified: October 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Hypotension
Vascular Diseases
Cardiovascular Diseases
Norepinephrine
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents